Idexx Laboratories (IDXX) EBIT (2009 - 2026)

Idexx Laboratories' EBIT history runs 18 years deep, the most recent figure standing at $362.6 million for Q1 2026.

• In Q1 2026, EBIT rose 14.55% year-over-year to $362.6 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 22.7% YoY), while the FY2025 annual figure was $1.4 billion, up 20.53% from the prior year.
• EBIT for Q1 2026 stood at $362.6 million, up from $315.6 million in the prior quarter.
• The five-year high for EBIT was $373.0 million in Q2 2025, with the low at $179.1 million in Q2 2022.
• The 5-year median for EBIT is $280.4 million (2023), against an average of $285.1 million.
• The sharpest annual moves came in 2022 and 2023: EBIT tumbled 30.93% in 2022, then soared 65.38% in 2023.
• Idexx Laboratories' EBIT stood at $226.5 million in 2022, then climbed by 8.29% to $245.3 million in 2023, then rose by 6.68% to $261.7 million in 2024, then advanced by 20.6% to $315.6 million in 2025, then climbed by 14.89% to $362.6 million in 2026.
• Business Quant data shows IDXX's EBIT at $362.6 million in Q1 2026, $315.6 million in Q4 2025, and $354.8 million in Q3 2025.